Karen Dineen Wagner1, Laura Redden2, Robert A Kowatch2, Timothy E Wilens2, Scott Segal2, Kiki Chang2, Patricia Wozniak2, Namita V Vigna2, Walid Abi-Saab2, Mario Saltarelli2. 1. Dr. Wagner is with the University of Texas Medical Branch; Dr. Redden is with the Abbott Laboratories; Dr. Kowatch is with the University of Cincinnati Medical Center; Dr. Wilens is with the Massachusetts General Hospital; Dr. Segal is with the Segal Institute for Clinical Research; Dr. Chang is with the Stanford University School of Medicine; Drs. Vigna, Abi-Saab, and Saltarelli are with Abbott Laboratories and the Divalproex ER Pediatric Mania Group; and Dr. Wozniak is with Advanced Clinical Research Services. Electronic address: kwagner@utmb.edu. 2. Dr. Wagner is with the University of Texas Medical Branch; Dr. Redden is with the Abbott Laboratories; Dr. Kowatch is with the University of Cincinnati Medical Center; Dr. Wilens is with the Massachusetts General Hospital; Dr. Segal is with the Segal Institute for Clinical Research; Dr. Chang is with the Stanford University School of Medicine; Drs. Vigna, Abi-Saab, and Saltarelli are with Abbott Laboratories and the Divalproex ER Pediatric Mania Group; and Dr. Wozniak is with Advanced Clinical Research Services.
Abstract
OBJECTIVE: To compare the efficacy and safety of divalproex extended-release (ER) to placebo in a 28-day double-blind study of bipolar disorder in children and adolescents and evaluate the safety of divalproex ER in a 6-month open-label extension study. METHOD: In the double-blind study, 150 patients (manic or mixed episode, aged 10-17 years) with baseline Young Mania Rating Scale (YMRS) score of 20 or higher were randomized to once-daily placebo or divalproex ER, which was titrated to clinical response or serum valproate concentrationof 80 to 125 microg/mL. Sixty-six patients enrolled in the extension study. RESULTS: In the double-blind study, a treatment effect was not observed with divalproex ER based on change in mean YMRS score (divalproex ER -8.8 [n = 74]; placebo -7.9 [n = 70]) or secondary measures. Divalproex was similar to placebo based on incidence of adverse events. Four subjects treated with divalproex ER and three treated with placebo discontinued because of adverse events. Mean ammonia levels increased in the divalproex ER group, but only one patient was symptomatic. In the long-term study, YMRS scores decreased modestly (2.2 points from baseline). The most common adverse events were headache and vomiting. CONCLUSIONS: The results of the study do not provide support for the use of divalproex ER in the treatment of youths with bipolar I disorder, mixed or manic state. Further controlled trials are required to confirm or refute the findings from this study.
RCT Entities:
OBJECTIVE: To compare the efficacy and safety of divalproex extended-release (ER) to placebo in a 28-day double-blind study of bipolar disorder in children and adolescents and evaluate the safety of divalproex ER in a 6-month open-label extension study. METHOD: In the double-blind study, 150 patients (manic or mixed episode, aged 10-17 years) with baseline Young Mania Rating Scale (YMRS) score of 20 or higher were randomized to once-daily placebo or divalproex ER, which was titrated to clinical response or serum valproate concentration of 80 to 125 microg/mL. Sixty-six patients enrolled in the extension study. RESULTS: In the double-blind study, a treatment effect was not observed with divalproex ER based on change in mean YMRS score (divalproex ER -8.8 [n = 74]; placebo -7.9 [n = 70]) or secondary measures. Divalproex was similar to placebo based on incidence of adverse events. Four subjects treated with divalproex ER and three treated with placebo discontinued because of adverse events. Mean ammonia levels increased in the divalproex ER group, but only one patient was symptomatic. In the long-term study, YMRS scores decreased modestly (2.2 points from baseline). The most common adverse events were headache and vomiting. CONCLUSIONS: The results of the study do not provide support for the use of divalproex ER in the treatment of youths with bipolar I disorder, mixed or manic state. Further controlled trials are required to confirm or refute the findings from this study.
Authors: Mani N Pavuluri; James A Ellis; Ezra Wegbreit; Alessandra M Passarotti; Michael C Stevens Journal: Behav Brain Res Date: 2011-10-08 Impact factor: 3.332
Authors: Barbara Geller; Joan L Luby; Paramjit Joshi; Karen Dineen Wagner; Graham Emslie; John T Walkup; David A Axelson; Kristine Bolhofner; Adelaide Robb; Dwight V Wolf; Mark A Riddle; Boris Birmaher; Nasima Nusrat; Neal D Ryan; Benedetto Vitiello; Rebecca Tillman; Philip Lavori Journal: Arch Gen Psychiatry Date: 2012-01-02
Authors: Mani N Pavuluri; David B Henry; Robert L Findling; Stephanie Parnes; Julie A Carbray; Tahseen Mohammed; Philip G Janicak; John A Sweeney Journal: Bipolar Disord Date: 2010-09 Impact factor: 6.744
Authors: Benedetto Vitiello; Mark A Riddle; Gayane Yenokyan; David A Axelson; Karen D Wagner; Paramjit Joshi; John T Walkup; Joan Luby; Boris Birmaher; Neal D Ryan; Graham Emslie; Adelaide Robb; Rebecca Tillman Journal: J Am Acad Child Adolesc Psychiatry Date: 2012-07-31 Impact factor: 8.829